Literature DB >> 10684309

Interaction of yellow fever virus French neurotropic vaccine strain with monkey brain: characterization of monkey brain membrane receptor escape variants.

H Ni1, K D Ryman, H Wang, M F Saeed, R Hull, D Wood, P D Minor, S J Watowich, A D Barrett.   

Abstract

Binding of yellow fever virus wild-type strains Asibi and French viscerotropic virus and vaccine strains 17D and FNV to monkey brain and monkey liver cell membrane receptor preparations (MRPs) was investigated. Only FNV bound to monkey brain MRPs, while French viscerotropic virus, Asibi, and FNV all bound to monkey liver MRPs. Four monkey brain and two mouse brain MRP escape (MRP(R)) variants of FNV were selected at pH 7.6 and 6.0. Three monkey brain MRP(R) variants selected at pH 7.6 each had only one amino acid substitution in the envelope (E) protein in domain II (E-237, E-260, or E274) and were significantly attenuated in mice following intracerebral inoculation. Two of the variants were tested in monkeys and retained parental neurotropism following intracerebral inoculation at the dose tested. We speculate that this region of domain II is involved in binding of FNV E protein to monkey brain and is, in part, responsible for the enhanced neurotropism of FNV for monkeys. A monkey brain MRP(R) variant selected at pH 6.0 and two mouse brain MRP(R) variants selected at pH 7.6 were less attenuated in mice, and each had an amino acid substitution in the transmembrane region of the E protein (E-457 or E-458).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10684309      PMCID: PMC111783          DOI: 10.1128/jvi.74.6.2903-2906.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  8 in total

Review 1.  The recognition event between virus and host cell receptor: a target for antiviral agents.

Authors:  T L Lentz
Journal:  J Gen Virol       Date:  1990-04       Impact factor: 3.891

2.  Structural requirements for low-pH-induced rearrangements in the envelope glycoprotein of tick-borne encephalitis virus.

Authors:  K Stiasny; S L Allison; A Marchler-Bauer; C Kunz; F X Heinz
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

3.  Genetic variation in yellow fever virus: duplication in the 3' noncoding region of strains from Africa.

Authors:  E Wang; S C Weaver; R E Shope; R B Tesh; D M Watts; A D Barrett
Journal:  Virology       Date:  1996-11-15       Impact factor: 3.616

Review 4.  Yellow fever vaccines.

Authors:  A D Barrett
Journal:  Biologicals       Date:  1997-03       Impact factor: 1.856

5.  The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution.

Authors:  F A Rey; F X Heinz; C Mandl; C Kunz; S C Harrison
Journal:  Nature       Date:  1995-05-25       Impact factor: 49.962

6.  Attenuation of Japanese encephalitis virus by selection of its mouse brain membrane receptor preparation escape variants.

Authors:  H Ni; A D Barrett
Journal:  Virology       Date:  1998-02-01       Impact factor: 3.616

7.  Comparison of the genomes of the wild-type French viscerotropic strain of yellow fever virus with its vaccine derivative French neurotropic vaccine.

Authors:  E Wang; K D Ryman; A D Jennings; D J Wood; F Taffs; P D Minor; P G Sanders; A D Barrett
Journal:  J Gen Virol       Date:  1995-11       Impact factor: 3.891

8.  Nucleotide sequence variation of the envelope protein gene identifies two distinct genotypes of yellow fever virus.

Authors:  G J Chang; B C Cropp; R M Kinney; D W Trent; D J Gubler
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

  8 in total
  15 in total

1.  Biophysical characterization and vector-specific antagonist activity of domain III of the tick-borne flavivirus envelope protein.

Authors:  S Bhardwaj; M Holbrook; R E Shope; A D Barrett; S J Watowich
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

2.  The envelope glycoprotein domain III of Dengue virus type 2 induced the expression of anticoagulant molecules in endothelial cells.

Authors:  Lien-Cheng Chen; Trai-Ming Yeh; Yi-Ying Lin; Yi-Fen Wang; Shu-Jem Su; Chang-Yu Chen; Kuan-Hua Lin; Miao-Chen Chou; Huey-Wen Shyu
Journal:  Mol Cell Biochem       Date:  2010-06-05       Impact factor: 3.396

3.  ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy.

Authors:  Juan Arroyo; Chuck Miller; John Catalan; Gwendolyn A Myers; Marion S Ratterree; Dennis W Trent; Thomas P Monath
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

4.  Neuroblastoma cell-adapted yellow fever 17D virus: characterization of a viral variant associated with persistent infection and decreased virus spread.

Authors:  Leonsia A Vlaycheva; Thomas J Chambers
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

5.  Neuroadapted yellow fever virus 17D: genetic and biological characterization of a highly mouse-neurovirulent virus and its infectious molecular clone.

Authors:  T J Chambers; M Nickells
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

6.  An external loop region of domain III of dengue virus type 2 envelope protein is involved in serotype-specific binding to mosquito but not mammalian cells.

Authors:  Jan-Jong Hung; Meng-Ti Hsieh; Ming-Jer Young; Chuan-Liang Kao; Chwan-Chuen King; Wen Chang
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

Review 7.  Current status and future prospects of yellow fever vaccines.

Authors:  Andrew S Beck; Alan D T Barrett
Journal:  Expert Rev Vaccines       Date:  2015-09-14       Impact factor: 5.217

8.  Neuroadapted yellow fever virus strain 17D: a charged locus in domain III of the E protein governs heparin binding activity and neuroinvasiveness in the SCID mouse model.

Authors:  Janice Nickells; Maria Cannella; Deborah A Droll; Yan Liang; William S M Wold; Thomas J Chambers
Journal:  J Virol       Date:  2008-10-08       Impact factor: 5.103

9.  Neuroadapted yellow fever virus 17D: determinants in the envelope protein govern neuroinvasiveness for SCID mice.

Authors:  Michael Nickells; Thomas J Chambers
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

Review 10.  Changing patterns of West Nile virus transmission: altered vector competence and host susceptibility.

Authors:  Aaron C Brault
Journal:  Vet Res       Date:  2009-05-01       Impact factor: 3.683

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.